Navigation Links
InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
Date:9/30/2009

carcinogenicity following lifetime exposure to INT131. These results are enabling for INT131 to initiate planned Phase 3 clinical studies.

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. INT131 has been designed to provide a safer therapeutic tool for physicians and patients, which is complementary to available classes of medications, and allows for powerful glucose control and the opportunity for modification of the underlying disease. As a SPPARM, INT131 selectively modulates PPAR-gamma, and is ideally positioned to safely improve insulin resistance, addressing an important unmet medical need.

About InteKrin (www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

SOURCE InteKrin Therapeutics Inc.


'/>"/>
SOURCE InteKrin Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
3. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 According to ... & Intravascular Systems- Warming & Cooling), Application (Acute ... & Anesthesiologist, Nursing & Paramedical Staff) - Global ... report studies the global Temperature Management Market over ... market is expected to reach $2.5 Billion by ...
(Date:9/18/2014)... 18, 2014 This BCC Research report discusses the medical ... market growth and size, and opportunities for different devices and ... 2018. Patent analysis in the report focuses on technological trends ... Europe and Japan . ... discuss the global medical device technologies market. - Analyze market ...
(Date:9/18/2014)... FRANCISCO , Sept. 18, 2014   Fruit ... has secured an initial seed round of funding. ... investments, was led by a series of individual investors, ... investors whom participated in the initial round are; ... Valley Medical Center Urologist Stacy Childs, Rapha Family Medicine ...
Breaking Medicine Technology:Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3
... SynCardia Systems, Inc. ( www.syncardia.com ), manufacturer of ... CE (Europe) approved Total Artificial Heart, announced record-setting revenue ... part to Certified Centers performing a record number of ... . (Photo: http://photos.prnewswire.com/prnh/20120517/LA08709 ) ...
... 17, 2012  SuccessEHS, a nationally recognized electronic ... software vendor, kicked off its annual Customer ... Birmingham. SuccessEHS selected "Forward Together" as ... commitment to helping its clients successfully navigate the ...
Cached Medicine Technology:SynCardia Posts Record Revenue and Profit in Q1 2012 2SynCardia Posts Record Revenue and Profit in Q1 2012 3SuccessEHS "Forward Together" Customer Conference Begins 2SuccessEHS "Forward Together" Customer Conference Begins 3
(Date:9/18/2014)... (PRWEB) September 18, 2014 Companies in ... refine carbon dioxide, selling it to downstream industries in ... for carbon dioxide are food and beverage manufacturers. Food ... as fruits, vegetables or pizzas. The gas is also ... use the compound to carbonate soft drinks, beer and ...
(Date:9/18/2014)... Amy Norton HealthDay Reporter , ... dose of a common antidepressant can quickly alter the way ... The findings, reported online Sept. 18 in Current ... response to widely prescribed antidepressants. Experts said the hope is ... are likely to benefit from a drug -- and which ...
(Date:9/18/2014)... (CHEST) together with the Chinese Thoracic Society (CTS) ... that CHEST World Congress 2016 will be held ... and sleep medicine from around the world are ... spring 2016. , CHEST World Congress 2016 ... training, keynote addresses, presentations by leading health-care experts, ...
(Date:9/18/2014)... City, UT (PRWEB) September 18, 2014 ... America will be recognizing their shared fundraising impact on ... Thursday, Sept. 25. , The first-ever Dance Marathon Day ... than $20 million projected to be raised by college ... community’s CMN Hospital. Donations generated through Dance Marathon campus ...
(Date:9/18/2014)... Baltimore, MD (PRWEB) September 18, 2014 ... Award-winning celebrity and wellness advocate, and Frank Davis, ... Activz Whole-food Nutrition, are pleased to announce ... 150+ ways to make delicious, nutrition-packed meals using ... book is the next step in the ...
Breaking Medicine News(10 mins):Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3
... Miguel ngel Fullana, researcher at the Universitat Autnoma ... psychologist the Institute of Psychiatric Treatment of Hospital ... College Institute of Psychiatry, London, has carried out ... obsessive-compulsive rituals in childhood with the risk of ...
... March 4 Beginning February 2009, a la mode will ... camisoles for women who have or will undergo mastectomy, lumpectomy ... bra fitters have been trained and certified by Amoena to ... provide a safe, comfortable and supportive environment for women of ...
... Homeopathic Product Offers Clinically Proven Effective Alternative to Controversial ... popular belief, common colds do not decrease ... the availability of a new, naturally safe cold remedy, ... to combat this prevalent virus, which actually strikes more ...
... 4 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... Commercial Development of BioMarin, will present a company update at ... March 11th, 2009 at 2:30 p.m. ET. Interested parties ... via the investor section of the BioMarin website, www.BMRN.com ...
... Inc. (Nasdaq: CLRT ), a premier technology and ... announced that it has rescheduled the release of its financial ... to Wednesday, March 11th in order to complete its year ... of its Form 10-K for the year ended December 31, ...
... Calif., March 4 Scanning the CDC website can ... The CDC concedes that over two million patients will ... many as 100,000 will die as a result. CDC ... morbidity risks and add 9 additional days to a ...
Cached Medicine News:Health News:Obsessive symptoms in childhood can multiply the probabilities of an obsessive compulsive disorder 2Health News:a la mode Bra Fitting Specialty Boutique Now Has Trained Fitters and Products for Women Who Are Post Op Mastectomy or Lumpectomy 2Health News:Naturally Safe Zucol(TM) Brings Europe's Leading Cold Remedy to United States 2Health News:Naturally Safe Zucol(TM) Brings Europe's Leading Cold Remedy to United States 3Health News:Naturally Safe Zucol(TM) Brings Europe's Leading Cold Remedy to United States 4Health News:BioMarin to Present at the Barclays Capital Global Healthcare Conference 2Health News:Clarient Reschedules Fourth Quarter and Year-End 2008 Financial Results Release To Wednesday, March 11th; Conference Call and Webcast Rescheduled For 5:00 PM EDT That Day 2Health News:Mercy Hospital at Folsom Acquires Advanced Germicidal Technology to Battle MRSA, C. diff, Acinetobacter and Other Drug-Resistant Pathogens 2
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... The first mobile clinical assistant ... A convergence of technologies in the ... you normally do during your,shift such ... and take pictures using one single ...
Assay development using client's antibodies and antigens to meet diagnostic target...
Medicine Products: